You are here

  • Home
  • Archive
  • Volume 62, Issue Suppl 1
  • PWE-139 Further Validation of Terminal Peptide of Procollagen Iii (PIIINP) for the Detection and Assessment of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease

Article Text

Article menu

Download PDFPDF

Liver
PWE-139 Further Validation of Terminal Peptide of Procollagen Iii (PIIINP) for the Detection and Assessment of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease
Free
  1. S Tanwar1,
  2. J Parkes2,
  3. B J Hogan1,
  4. D Schuppan3,
  5. M Pinzani1,
  6. M J P Arthur4,
  7. A Burt5,
  8. W M Rosenberg1
  1. 1UCL Institute for Liver & Digestive Health, University College London, London
  2. 2Public Health Sciences & Medical Statistics, Faculty of Medicine, University of Southampton, Southampton, UK
  3. 3University of Mainz, Mainz, Germany
  4. 4University of Leeds, Leeds
  5. 5Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Abstract

Introduction PIIINP has recently been shown to discriminate between simple steatosis (SS) and NASH both in patients without advanced fibrosis and in patients with all degrees of fibrosis1. In this study we validated PIIINP as a biomarker of NASH in a cohort of patients with biopsy proven NAFLD and evaluated its performance at the proposed diagnostic thresholds.

Methods 71 patients with NAFLD and no evidence of other liver disease were included in this study. Liver biopsies were performed on all patients and analysed by a expert liver histopathologist. All liver biopsies were of suitable size for analysis (> 12mm and > 5 portal tracts) and classified in a dichotomous manner into those with SS or histological NASH. Fibrosis was assessed using the Scheuer classification. Serum samples were taken at the time of liver biopsy.

Results 14 of the 60 patients with non-advanced fibrosis (4-F0, 18-F1.1-F2) and all 11 patients with advanced fibrosis (9-F3, 2-F4) had NASH respectively. The AUROC of PIIINP in discriminating between SS and NASH in patients with non-advanced fibrosis and all degrees of fibrosis was 0.81 (CI 0.69–0.94) and 0.87 (CI 0.79–0.96) respectively. In comparison, the ability of ALT to discriminate between SS and NASH ranged between 0.43–0.45. The performance of the recently proposed thresholds PIIINP in their ability to diagnose NASH in our population is displayed in the table.

View this table:
Abstract PWE-139 Table

Conclusion PIIINP discriminates between SS and NASH. The performance of the proposed diagnostic thresholds is comparable to that reported in the original publication of this biomarker. Our results suggest that PIIINP can be used to detect the minority of patients with NAFLD who have NASH and are at risk of developing progressive fibrosis.

Disclosure of Interest None Declared.

Reference

  1. Tanwar S et al. Validation of Terminal Peptide of Procollagen III for the Detection and Assessment of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease. Hepatology. 2013 Jan; 57(1):103–11. doi: 10.1002/hep.26030. PMID: 22930399

https://doi.org/10.1136/gutjnl-2013-304907.427

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.